

References

S-217

1. InterQual Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
2. American Cancer Society. High-dose Chemotherapy and Stem Cell Transplant for Hodgkin Lymphoma. 2017.
3. Winkfield KM, Advani RH, Ballas LK, et al. ACR Appropriateness Criteria(R) recurrent Hodgkin lymphoma. *Oncology* (Williston Park). 2016; 30(12):1099-1103, 1106-1098.
4. Adult Hodgkin Lymphoma Treatment (PDQ®)-Health Professional Version. 2017. Accessed February 14, 2020.
5. NCCN Clinical Practice Guidelines in Oncology: Hodgkin disease/lymphoma. Version 3.2021. Accessed March 16, 2021
6. Hodgkin Lymphoma Stages. Accessed February 14, 2020.
7. Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: A systematic review and meta-analysis. *Bone Marrow Transplant.* : 51(4):521-528.
8. Gao L, Xiang X, Zhang C, et al. Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: A multicenter retrospective cohort study. *Hematology.* 2019; 24(1):225-231.
9. Martínez C, Gayoso J, Canals C, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: A registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. *J Clin Oncol.* 2017; 35(30):3425-3432.
10. National Cancer Institute (NCI). Adult Hodgkin Lymphoma Treatment (PDQ) - Health Professional Version. Updated January 14, 2021.
11. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* 2016;127(20):2375-2390.
12. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood.* 2018;132(25): 2639-2642.
13. Smith EP, Li H, Friedberg JW, et al. Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent Hodgkin lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). *Biol Blood Marrow Transplant.* 2018;24(4):700-707.

14. Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. *Am J Hematol.* 2017;92(9):879-884.
15. Sibon D, Morschhauser F, Resche-Rigon M, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. *Haematologica.* 2016;101(4):474-481.